William Eward, MD, DVM, discusses the unmet need for novel agents in tenosynovial giant cell tumor and sarcoma.
William Eward, MD, DVM
Advertisement
Articles by William Eward, MD, DVM
William Eward, MD, DVM, discusses the approval of pexidartinib to treat patients with tenosynovial giant cell tumor.
Advertisement
Latest Updated Articles
Dr. Eward on FDA Approval of Pexidartinib in TGCTOctober 30th 2019
Dr. Eward on the Unmet Need for Novel Agents for TGCT and SarcomaFebruary 13th 2020
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to 64Cu-SAR-bisPSMA for PSMA PET in Biochemically Recurrent Prostate Cancer
2
Detalimogene Responses Improve With Longer Follow-Up in BCG-Unresponsive NMIBC Ahead of BLA Submission
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
5